BiotechTube
Home/Pipeline/Cannabics® BRST-33

Cannabics® BRST-33

Breast Cancer

PreclinicalActive

Key Facts

Indication
Breast Cancer
Phase
Preclinical
Status
Active
Company
CNBX Pharmaceuticals

About CNBX Pharmaceuticals

CNBX Pharmaceuticals is a clinical-stage biotech company developing a pipeline of cannabinoid-based drug candidates for cancer and neuropsychiatric disorders. Its core asset, RCC-33, is positioned as a first-in-class candidate for colorectal cancer, currently in late preclinical stages preparing for an IND. The company utilizes an in-house drug discovery platform centered on high-throughput screening of cannabinoid formulations against various cancer types. Leadership combines business acumen with scientific and clinical expertise, supported by a notable advisory board in oncology.

View full company profile

Therapeutic Areas

OncologyNeuropsychiatryGastroenterology

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
GCT-007Global Cancer TechnologyResearch
NDESContinuity BiosciencesPre-clinical
INP12InnoUpClinical
Dedicated Breast Radiotherapy SystemEhmet HealthCommercial